School of Pharmacy

Sean D. Sullivan

Professor and Dean, School of Pharmacy

CHOICE Faculty, Office of the Dean, Pharmacy Faculty, School Faculty

Telephone: (206) 685-8153

Email: sdsull@uw.edu

Office Location: University of Washington 1959 NE Pacific Ave, H-364, Box 357631 Seattle, WA 98195-7630

Positions

Professor of Pharmacy, School of Pharmacy, Public Health Sciences Division, Fred Hutchinson Cancer Research Center; Member, Institute for Public Health Genetics, University of Washington

Education

  • BSc.Pharm 1983 Oregon State University, College of Pharmacy
  • M.Sc. 1986 University of Texas, College of Pharmacy (Administrative and Economic Sciences)
  • Ph.D. 1992 University of California, Berkeley (Health Economics and Policy)

Research Interests

  • Economic evaluation of pharmaceuticals
  • Health technology assessment
  • Medical decision making

Courses Taught

  • PHARM 541 – Pharmacy, Health and Society

Biography

Sean D. Sullivan, BScPharm, MSc, PhD, is Professor and Dean, School of Pharmacy. He holds a joint appointment as Professor of Health Services in the School of Public Health. He holds adjunct appointments in the School of Medicine, the Public Health Sciences Division at the Fred Hutchinson Cancer Research Center, and at the Kaiser Permanente Washington Health Research Institute.

He completed training in pharmacy at Oregon State University in 1983, obtained a master’s degree at the University of Texas in 1986 and a PhD in health economics and policy at the University of California, Berkeley in 1992.

Dr. Sullivan has authored more than 400 articles, book chapters and reports. In many of these, he has assessed the evidence and applications of medical technology in relation to coverage and reimbursement decisions. His research interests include health technology assessment, medical decision-making, and economic evaluation of medical technology, including pharmaceuticals. He is past president of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and past chair of the Academy of Managed Care Pharmacy (AMCP) Executive Committee of the Format for Formulary Submissions – the United States evidence-based guidelines for formulary decision making.

Dr. Sullivan was a member of the Medicare Evidence Development and Coverage Advisory Committee, a member of the Regence Blue Shield and Premera Blue Cross P/T Committee, and Chair of the Premera Blue Cross Value Assessment Committee. He was awarded the 2014 Stephen G. Avey Lifetime Achievement Award from the Academy of Managed Care Pharmacy (AMCP), the 2015 APhA Academy of Pharmaceutical Research Sciences (APRS) Research Achievement Award, and was named an ICON of Pharmacy (2019) from Oregon State University.

Selected Publications

  • Bansal A, Sullivan SD, Lin V, Purdum A, Navale L, Ramsey SD. Estimating Long-Term Survival for Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma Treated with CAR-T Therapy: A Comparison of Standard and Mixture Cure Models. Medical Decision Making 2019 Apr;39(3):294-298.
  • Woo L, Smith HE, Sullivan SD. The economic burden of chronic obstructive pulmonary disease in the Asia-Pacific region: A systematic review. Value in Health Regional Issues 2019 May 18:121-131.
  • Drummond MF, Neuman PJ, Sullivan SD, Toumi M, Dabbous O, Fricke F-U, Tunis S. Analytic considerations and a reference case for economic evaluations of gene therapy replacement. Value in Health 2019 Jun;22(6):661-668.
  • Barger SA, Sullivan SD, Watabayashi K, et al. Effective Stakeholder Engagement: Design and Implementation of a Clinical Trial to Improve Cancer Care. BMC Medical Research Methodology 2019 Jun 11;19(1):119.
  • Sullivan SD, Nicholls CJ, Gupta RA, Meron AA, Wu J, Westerbacka J, Bosnyak Z, Frias JP, Bailey TS. Comparable Glycemic Control and Hypoglycemia in Adults with Type 2 Diabetes after Initiating Insulin Glargine 300 units/mL or Insulin Degludec: DELIVER Naive D Real-World Study. Diabetes, Obesity and Metabolism2019 Sep;21(9):2123-2132.
  • Steuten L, Garmo V, Phatak H, Sullivan SD, Nghiem P, Ramsey SD. Treatment Patterns, Total Healthcare Costs, and Overall Survival of Advanced Merkel Cell Carcinoma in the United States. Applied Health Economics and Health Policy 2019 Oct;17(5):733-740.
  • Ramsey SD, Shankaran V, Sullivan SD. Basket Cases: How real-world testing for drugs approved based on basket trials might lead to false diagnoses, patient risks, and squandered resources. Journal of Clinical Oncology 2019 Dec 20;37(36):3472-3474.
  • Freemantle N, Sullivan SD, et al. Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus. Curr Med Res Opin 2020 Jan 19:1-11
  • Landaas EJ, Hansen RN, Baird GS, Flum DR, Sullivan SD. Integrating Formal Technology Assessment into an Integrated Health Care Delivery System: Smart Innovation. Int J of Tech Ass in Health Care 2020;36(1):58-63.
  • Johnston K, Danchenko N, Hansen RN, Dinet J, Liovas A, Armstrong A, Baines S, Sullivan SD. Cost effectiveness and impact on quality of life of abobotulinumtoxinA in the treatment of children with lower limb spasticity in Canada. Journal of Medical Economics 2020 Feb 7:1-10.
  • Khandelwal N, Sullivan SD. An Effective Behavioral Nudge in the Operating Room. Anesthesiology 2020 May;132(5):942-943.